AbCellera Biologics (ABCL) EBITDA Margin Growth (1y) (2021 - 2026)

AbCellera Biologics (ABCL) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1,552.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -170.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1,276.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 AbCellera Biologics 1.62 Bn 1.62 Bn - 78,783.00

Historic Data

Download Data
DateValue
Mar 31, 2026 78,783.00
Dec 31, 2025 137,697.00
Sep 30, 2025 58,763.00
Jun 30, 2025 98,593.00
Mar 31, 2025 -92,810.00
Dec 31, 2024 -72,108.00
Sep 30, 2024 -60,763.00
Jun 30, 2024 -76,514.00
Mar 31, 2024 -1,937.00
Dec 31, 2023 -54,427.00
Sep 30, 2023 -86,901.00
Jun 30, 2023 -49,274.00
Mar 31, 2023 -60,316.00
Dec 31, 2022 -23,388.00
Sep 30, 2022 54,731.00
Jun 30, 2022 716.00
Mar 31, 2022 -691.00
Dec 31, 2021 -1,880.00
Sep 30, 2021 -49,121.00
Jun 30, 2021 -1,784.00